Renal Biomarker Market
Renal Biomarker Market By Biomarker, Diagnostic Technique, End User & Region | Forecast 2022 to 2032
Renal Biomarkers- Reliable Solutions for Proper Management Of Kidney Diseases! Find Out More with FMI
Renal Biomarker Market Outlook (2022 to 2032)
A summary of Renal Biomarker Market development:
[250 Pages Report] Global demand for renal biomarkers is expected to rise at a yearly growth rate of 7.0% Y-o-Y to $2.6 billion by 2032, supported by:
- global increases in the incidences of kidney diseases
- large geriatric population, notably in developing regions
- increasing prevalence of multiple co-morbidities
- rising incidences of chronic diseases such as diabetes, obesity, and hypertension
- an increment in the vulnerable aging population around the globe
Renal biomarkers are cells, proteins, lipids, microRNAs, genes, metabolites, or proteomic patterns present in a urinalysis. They assist in determining the glomerular filtration rate (GFR) of kidneys to analyze their proper functioning and evaluate pathogenic processes or pharmacological responses to therapeutic interventions. As they also aid in predicting disease progression and computing drug dosage, renal biomarkers find extensive applications in hospitals and diagnostic laboratories across the globe.
Furthermore, increasing investments in research and development is one of the major factors that is anticipated to boost the market growth, as renal biomarkers are widely used in preclinical and clinical trials, to assess the safety of new drugs.
|
Attribute |
Key Statistics |
|
Renal Biomarker Market Base Value (2021) |
US$ 1.2 Billion |
|
Estimated Market Value (2022) |
US$ 1.3 Billion |
|
Projected Market Value (2032) |
US$ 2.6 Billion |
|
Value-based CAGR (2022 to 2032) |
7.4% |
|
Market Share of Top 5 Countries |
56.3% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Development of Renal Biomarkers in North America Region Drives Global Growth
North America currently dominates the market for renal biomarkers, and it is expected to continue its stronghold for a few more years. In the North American region, the United States holds the largest market share. In the past decade, there was a significant increase in the number of US FDA-approved drug labels containing information on molecular biomarkers.
Almost every pharmaceutical company has been developing molecular biomarker programs, either through partnerships or other ventures. The rising prevalence of chronic kidney disorders among people in the United States is a major factor attributed to the increasing usage of renal biomarkers for effective diagnosis and to boost the market growth in this region. For example, the Centers for Disease Control and Prevention (CDC) published in 2021 that more than 1 in 7, nearly 37 million people in the United States are estimated to have chronic kidney disease (CKD).
Additionally, the increasingly vulnerable aging population that is prone to chronic kidney diseases in the United States is also contributing to the rising demand for early-stage diagnosis and effective treatment, thereby contributing to the growth of the market. For instance, in 2021, the Centers for Disease Control and Prevention (CDC) published that chronic kidney diseases were the most common in people aged 65 years or older and contributed to 38% of the affected population in the United States.
In March 2022, Aravive Inc. demonstrated positive results from Phase 1b/2 trial of batiraxcept in clear cell renal cell cancer (ccRCC) and from a biomarker high subgroup. Therefore, such clinical trials will boost the development of biomarker tests in the country. This will subsequently drive market growth. Thus, owing to the aforementioned factors, the studied market is expected to grow significantly during the forecast period.
Opportunities in the Renal Biomarker Sector
Chronic kidney disease (CKD), a non-communicable disease with considerable morbidity and mortality, has gradually become a public health concern globally and its main risk factors are diabetes, hypertension, and heart disease. The increasing number of individuals with CKD represents one of the key factors propelling the growth of the market.
Furthermore, renal biomarkers, including blood urea nitrogen (BUN), serum creatinine (SCr), urinary albumin/protein, and volume excretion, are used in the diagnosis of chronic kidney disease (CKD) and monitoring of the disease. Besides this, there is a growing interest of industry investors in novel single biomarkers and process-specific biomarker panels in human renal diseases around the world.
Appropriate screening, diagnosis, and management are necessary to prevent adverse CKD-associated outcomes, including cardiovascular disease, and end-stage kidney disease. For this purpose, renal biomarkers are being extensively used.
Renal biomarkers help to diagnose or identify patients that are at risk of developing kidney diseases. They have become ideal solutions for the early detection of renal disease, thereby allowing physicians to take timely decisions to reduce mortality rates.
Thus, growing need for identifying kidney diseases to take timely patient management decisions. including the administration of putative therapeutic agents will continue to boost the growth of the renal biomarker market during the forecast period.
The renal biomarker market held approximately 2.3% of the global biomarkers market, which stood at ~US$ 51.2 Billion in 2021.
Find your sweet spots for generating winning opportunities in this market.
Sales Analysis of Renal Biomarker Market from 2012 to 2021 Vs Market Outlook for 2022 to 2032
The global renal biomarker market is projected to grow at a healthy CAGR of 7.4% between 2022 and 2032, in comparison to the 6.8% CAGR registered from 2012 to 2021. The rising incidence of kidney diseases along with the growing need for early detection of these kidney diseases for proper management is a key factor driving demand in the renal biomarkers market.
The serum creatinine, which is a product of the breakdown of creatine and phosphocreatine, is readily filtered by the glomerulus and has been used specifically in the diagnosis of renal disease. Serum creatinine has been the gold standard for almost a century since it is widely available and reasonably priced.
Finding structural indicators of renal tubular injury in systemic circulation or the urine that are either directly produced by the kidney or accumulate as a result of tubular cell dysfunction after kidney damage has been the focus of research using novel technologies. These indicators of tubular health, which are related to the pathophysiology of kidney injury, may help with early diagnosis, localization of the injury, etiologic differentiation, and prognosis of renal diseases.
In hospitalized patients, acute kidney damage and chronic kidney disease (CKD) are common. More precise data about the likelihood of long-term progression to renal failure are needed to guide clinical decision-making.
CKD, which affects 13.4% of the adult population and results in 1.2 million fatalities annually, has been identified as a hidden epidemic and a significant public health issue. Kidney failure has a significant negative impact on global health since it is a substantial economic burden, a leading cause of morbidity and mortality worldwide, and a significant risk factor for cardiovascular diseases (CVD).
Thus, the application of renal biomarkers for the identification and assessment of renal function within institutional settings is set to be widely propelled by the growing incidence of kidney diseases.
What are the Key Trends Driving the Global Renal Biomarker Market?
“Advancements in Molecular Diagnostic Techniques to Bolster Market Growth”
Several targeted approaches have been developed to investigate new, early-specific biomarkers of CKD diagnosis, taking into consideration the fact that typical laboratory measures of deteriorating kidney function are hardly impacted in the early stages.
Omics techniques are gradually becoming acknowledged for their significance in the early diagnosis of CKD, although not being used frequently. For example, it has been discovered that proteomics is useful for detecting anti-M-type phospholipase A2 receptor auto-antibodies in the detection of primary membranous nephropathy (a condition that affects as many as 70% of cases).
The examination of the metabolome, genome, transcriptome, epigenome, and proteome, is made possible by high-throughput omics technology. Metabolomics seeks to characterize non-targeted, global small-molecule metabolite profiles in complex samples.
Thus, considering the efficiency of novel and emergent techniques such as omics, the market for renal biomarkers is set to witness a lucrative growth rate over the forecast years.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
What are the Factors Restraining Growth of the Renal Biomarker Market?
The most significant indicator of kidney function is the glomerular filtration rate (GFR). Unfortunately, most clinical and research situations make it difficult to assess GFR, hence estimation equations rely on renal indicators such as serum creatinine (SCr) and cystatin C. (CysC).
Other indicators, such as albuminuria, have shown to have strong relationships with disease progression and outcomes and may precede the reduction in kidney function. There are some potential alternatives available to fill the critical gap since currently used biomarkers typically have limitations in the chronic setting.
However, clinical evaluations of these alternatives are a lengthy process, considering the effects of emerging biomarkers on human anatomy. Moreover, with a lengthy and restrictive regulatory scenario, as well as product licensing activities, the market for renal biomarkers will likely observe a hindrance in terms of growth, during the forecast years.
Country-wise Insights
What Makes the USA the Most Dominant Renal Biomarker Market?
“Rising Cases of Chronic Kidney Disease Fostering Market Growth in the USA”
The USA dominated the North American renal biomarker market with a total market share of about 92.0% in 2021 and it is likely to expand at a robust CAGR during the forecast period.
The rising prevalence of chronic kidney disease along with high diagnostic screening rates is a key factor driving growth in the USA renal biomarker market. As per the Centers for Disease Control and Prevention (CDC), an estimated 37 million people in the USA suffer from chronic kidney disease and this number is likely to further surge during the upcoming years. With a high disease burden, the demand for diagnosis of renal function is propelled, which, in turn, is expected to boost the overall market for renal biomarkers within the country.
Similarly, increasing investments in research and development activities and the presence of some of the leading market players are anticipated to bolster market growth in the country during the next ten years.
What is the Growth Projection for Renal Biomarker Market in Germany?
“Presence of Favourable Reimbursement Policies Supporting Market Growth in Germany”
Germany held a market share of about 7.1% in the global renal biomarker market in 2021 and it is expected to grow at a healthy pace during the next ten years, owing to the rapid expansion of the healthcare industry and increase in diagnostic screening for detecting various chronic diseases at earlier stages.
Germany has a comprehensive healthcare system, and there have been continuous discussions over the benefits of paying for treatments under various coverage plans. Due to the existence of reimbursement policies and programs for both in-patient and outpatient procedures for the diagnosis of renal illness, the nation is expected to demonstrate a boost in terms of the total revenue growth of the renal biomarkers market.
What Makes China a Highly Lucrative Renal Biomarker Market?
“High Mortality Rate of CKD Fuelling Demand in China”
China held approximately 4.5% share in the global renal biomarker market in 2021 and it is poised to grow at a CAGR of 4.5% during the forecast period. The rise in mortality rates due to chronic kidney disease, favorable government support, and growing health awareness are some of the key factors driving market growth in China.
Similarly, technological advancement and modernization in healthcare techniques are expected to push the demand for renal biomarkers in the country during the forthcoming years.
Chronic kidney disease (CKD) morbidity and mortality have considerably increased in China over the past few years, along with the prevalence of metabolic disorders including diabetes and hypertension, which poses a serious danger to the health of the nation. Currently, China's national system for the prevention and control of chronic diseases is having a significant impact on lowering the prevalence of a number of serious chronic conditions.
Furthermore, the surge in the prevalence of end-stage kidney disease and massive consumption of healthcare resources in China as a result of the delayed and inefficient adoption of standardized patient treatment and interventions is positively impacting market growth in the country.
Category-wise Insights
Which is the Most Commonly Used Biomarker in Renal Biomarker Market?
“Functional Biomarkers are Mostly Used for Detection of Renal Injury”
The functional biomarker segment held a market share of around 43.6% in the global renal biomarker market in 2021 and it is likely to exhibit a strong growth rate during the forecast period. This can be attributed to the ability of functional biomarkers to estimate the nature and severity of kidney injury.
Functional biomarkers can be carefully validated in adequately planned prospective studies as well as employed as a decision-making tool in the clinical situation. The use of such biomarkers in conjunction with therapeutic treatment monitoring appears to be a promising strategy for treating both acute and chronic renal disorders. This segment thus dominates the overall renal biomarkers market.
Which is the Highly Sought-After Diagnostic Technique in Renal Biomarker Market?
“Demand to Remain High for ELISA in the Market”
As per FMI, Enzyme-linked immunosorbent assay (ELISA) held a market share of around 46.5% in the global renal biomarker market in 2021 and it is likely to retain its dominance even during the forecast period.
Due to its simple handling and rapid analysis, ELISA is ideal for the assessment of large sample numbers to evaluate renal function in at-risk patients. The ELISA can also be utilized for the assessment of treatment and postoperative care following kidney transplantation, based on specific empirical proof from ongoing studies.
Which is the Leading End User in Renal Biomarkers Market?
“Diagnostic Centres to Contribute Most to the Renal Biomarker Market Growth”
The diagnostic lab's segment held a revenue share of about 49.5% within the global renal biomarker market in 2021 and it is expected to grow at the highest CAGR during the forecast period. This can be attributed to the rising usage of renal biomarkers across diagnostic labs for the early identification of kidney diseases.
The global renal biomarkers market is expected to grow at a profitable rate over the projected years since laboratory testing and biomarkers play a crucial role in the treatment and diagnosis of kidney disease. People are showing a keen inclination towards opting for diagnostic tests at diagnostic centers for early detection of acute renal injury to enhance treatment outcomes in view of the rising global disease burden.
Competitive Landscape
Key market players within the renal biomarker market are concentrating on new product launches and approvals, investments in research and development, partnerships, acquisitions, and collaborations to gain a competitive edge in the market.
Key instances of development within the market include:
- SphingoTec GmbH reported the publication of unique study findings including their patented pencil kidney function biomarker in BMC Emergency Medicine in December 2019.
- In order to include novel kidney disease biomarkers found by the center's researchers in Renalytix AI's KidneyIntelX platform, the business expanded its collaboration with the Joslin Diabetes Center in April 2021.
Report Scope as per Renal Biomarker Industry Analysis
|
Attribute |
Details |
|
Estimated Market Size (2022) |
US$ 1.3 Billion |
|
Projected Market Size (2032) |
US$ 2.6 Billion |
|
Anticipated Growth Rate (2022 to 2032) |
7.4% CAGR |
|
Forecast Period |
2012 to 2021 |
|
Historical Data Available for |
2022 to 2032 |
|
Market Analysis |
US$ Billion for Value |
|
Key Regions Covered |
North America, Latin America, Europe, South Asia, East Asia, Oceania, and Middle East & Africa (MEA) |
|
Key Countries Covered |
The USA, Canada, Brazil, Mexico, Argentina, UK, Germany, Italy, Russia, Spain, France, BENELUX, India, Thailand, Indonesia, Malaysia, Japan, China, South Korea, Australia, New Zealand, Turkey, GCC Countries, North Africa, and South Africa |
|
Key Market Segments Covered |
Biomarker, Diagnostic Technique, End User, and Region |
|
Key Companies Profiled |
|
|
Report Coverage |
Market Forecast, Company Share Analysis, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives |
Key Market Segments Covered in Renal Biomarker Industry Research
By Biomarker:
- Functional Biomarker
- Serum Creatinine
- Serum Cystatin C
- Urine Albumin
- Up-Regulated Proteins
- Neutrophil Gelatinase-Associated Lipocalin
- Kidney Injury Molecule-1
- Interleukin-18
- Others
By Diagnostic Technique:
- Enzyme Linked Immunosorbent Assay (ELISA)
- Particle-Enhanced Turbidimetric Immunoassay (PETIA)
- Colorimetric Assay
- Chemiluminescent Enzyme Immunoassay (CLIA)
- Liquid Chromatography-Mass Spectrometry (LS-MS)
By End User:
- Diagnostic Labs
- Outpatient Clinics
- Research Centers
- Hospitals
By Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East and Africa (MEA)
Frequently Asked Questions
How big is the global renal biomarker market?
The global renal biomarker market size was valued at around US$ 1.2 Billion in 2021 and it is likely to reach a valuation of US$ 1.3 Billion in 2022.
What is the sales forecast for renal biomarker market through 2032?
Sales in the renal biomarker market are set to rise at 7.4% CAGR during the forecast period.
What is the projected valuation for renal biomarker market?
As per FMI, the global renal biomarker market is expected to touch a valuation of US$ 2.6 Billion by 2032.
At what rate did the renal biomarker market grow during the historical period of 2012 to 2021?
Demand for renal biomarkers increased at 6.8% CAGR from 2012 to 2021.
Which countries are driving the highest demand for renal biomarkers?
The USA, Japan, Germany, China, and the UK are the top countries driving demand for renal biomarkers, collectively accounting for most demand for around 56.3% market share.
What is the USA renal biomarker market outlook?
The USA accounts for around 92.0% share of the North American renal biomarker market in 2021.
Who are the top three manufacturers of renal biomarker market?
Abbott Laboratories, BioPorto Diagnostics AS, and F. Hoffmann-La Roche AG are the top three manufacturers of renal biomarker products.
How is the renal biomarker market shaping up in China?
China held a share of about 4.5% in the global renal biomarker market in 2021.
How big is the renal biomarker market in Japan?
Japan held a share of about 4.5% within the global renal biomarker market in 2021.
What is the growth projection for renal biomarker market in Germany?
The German renal biomarker market holds a share value of around 7.1% within the global renal biomarker market.
Table of Content
1. Executive Summary | Renal Biomarker Market 1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply Side Trends 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 2.3. Inclusions and Exclusions 3. Key Market Trends 3.1. Key Trends Impacting the Market 3.2. Healthcare Innovation / Development Trends 4. Key Success Factors 4.1. Key Strategies- By Manufacturers 4.2. Regulatory Impositions 4.3. Reimbursement Scenario 4.4. Disease Epidemiology 4.5. Pipeline Analysis 4.6. PESTEL Analysis 4.7. Porter’s Analysis 5. Market Background 5.1. Macro-Economic Factors 5.1.1. Global GDP Growth Outlook 5.1.2. Global Healthcare Expenditure Outlook 5.1.3. Global Biomarkers Market Outlook 5.2. Forecast Factors - Relevance & Impact 5.2.1. Growing Burden of Chronic Kidney Disease 5.2.2. Research and Development for Novel Biomarkers 5.2.3. Large Clinical Pipeline 5.2.4. Advancements in Proteomics and Transcriptomics 5.2.5. Prevalence of Diabetes and High Blood Pressure 5.2.6. Licensing and Regulation of Drugs 5.2.7. Increasing Ageing Population 5.2.8. Launch of Biomarker Test Kits 5.3. Market Dynamics 5.3.1. Drivers 5.3.2. Restraints 5.3.3. Opportunity Analysis 6. COVID-19 Crisis Analysis 6.1. COVID-19 and Impact Analysis 6.1.1. By Biomarker 6.1.2. By Diagnostic Technique 6.1.3. By End User 6.1.4. By Country 6.2. 2021 Market Scenario 7. Global Market - Pricing Analysis 7.1. Regional Pricing Analysis By Product 7.2. Pricing Break-up 7.2.1. Manufacturer-Level Pricing 7.2.2. Distributor Level Pricing 7.3. Global Average Pricing Analysis Benchmark 7.4. Pricing Assumptions 8. Global Market Demand (in Value or Size in US$ Million) Analysis 2012 to 2021 and Forecast, 2022 to 2032 8.1. Historical Market Value (US$ Million) Analysis, 2012 to 2021 8.2. Current and Future Market Value (US$ Million) Projections, 2022 to 2032 8.2.1. Y-o-Y Growth Trend Analysis 8.2.2. Absolute $ Opportunity Analysis 9. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, By Biomarker 9.1. Introduction / Key Findings 9.2. Historical Market Size (US$ Million) Analysis By Biomarker, 2012 to 2021 9.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Biomarker, 2022 to 2032 9.3.1. Functional Biomarker 9.3.1.1. Serum Creatinine 9.3.1.2. Serum Cystatin C 9.3.1.3. Urine Albumin 9.3.2. Up-Regulated Proteins 9.3.2.1. Neutrophil Gelatinase-Associated Lipocalin 9.3.2.2. Kidney Injury Molecule-1 9.3.2.3. Interleukin-18 9.3.3. Others 9.4. Market Attractiveness Analysis By Biomarker 10. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, By Diagnostic Technique 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ Million) Analysis By Diagnostic Technique, 2012 to 2021 10.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Diagnostic Technique, 2022 to 2032 10.3.1. Enzyme-Linked Immunosorbent Assay (ELISA) 10.3.2. Particle-Enhanced Turbidimetric Immunoassay (PETIA) 10.3.3. Colorimetric Assay 10.3.4. Chemiluminescent Enzyme Immunoassay (CLIA) 10.3.5. Liquid Chromatography-Mass Spectrometry (LS-MS) 10.4. Market Attractiveness Analysis By Diagnostic Technique 11. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, By End User 11.1. Introduction / Key Findings 11.2. Historical Market Size (US$ Million) Analysis By End User, 2012 to 2021 11.3. Current and Future Market Size (US$ Million) Analysis and Forecast By End User, 2022 to 2032 11.3.1. Diagnostic Labs 11.3.2. Outpatient Clinics 11.3.3. Research Centers 11.3.4. Hospitals 11.4. Market Attractiveness Analysis By End User 12. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, By Region 12.1. Introduction / Key Findings 12.2. Historical Market Size (US$ Million) Analysis By Region, 2012 to 2021 12.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Region, 2022 to 2032 12.3.1. North America 12.3.2. Latin America 12.3.3. Europe 12.3.4. East Asia 12.3.5. South Asia 12.3.6. Oceania 12.3.7. Middle East & Africa (MEA) 12.4. Market Attractiveness Analysis By Region 13. North America Market Analysis 2012 to 2021 and Forecast 2022 to 2032 13.1. Introduction 13.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2012 to 2021 13.3. Current and Future Market Size (US$ Million) Analysis & Forecast By Market Taxonomy, 2022 to 2032 13.3.1. By Country 13.3.1.1. The USA 13.3.1.2. Canada 13.3.2. By Biomarker 13.3.3. By Diagnostic Technique 13.3.4. By End User 13.4. Market Attractiveness Analysis 13.4.1. By Country 13.4.2. By Biomarker 13.4.3. By Diagnostic Technique 13.4.4. By End User 13.5. Market Trends 13.6. Key Market Participants - Intensity Mapping 13.7. Drivers and Restraints - Impact Analysis 13.8. Country-Level Analysis & Forecast 13.8.1. The USA Market Analysis 13.8.1.1. Introduction 13.8.1.2. Market Analysis and Forecast By Market Taxonomy 13.8.1.2.1. By Country 13.8.1.2.2. By Biomarker 13.8.1.2.3. By Diagnostic Technique 13.8.1.2.4. By End User 13.8.2. Canada Market Analysis 13.8.2.1. Introduction 13.8.2.2. Market Analysis and Forecast By Market Taxonomy 13.8.2.2.1. By Country 13.8.2.2.2. By Biomarker 13.8.2.2.3. By Diagnostic Technique 13.8.2.2.4. By End User 14. Latin America Market Analysis 2012 to 2021 and Forecast 2022 to 2032 14.1. Introduction 14.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2012 to 2021 14.3. Current and Future Market Size (US$ Million) Analysis & Forecast By Market Taxonomy, 2022 to 2032 14.3.1. By Country 14.3.1.1. Mexico 14.3.1.2. Brazil 14.3.1.3. Argentina 14.3.1.4. Rest of Latin America 14.3.2. By Country 14.3.3. By Biomarker 14.3.4. By Diagnostic Technique 14.3.5. By End User 14.4. Market Attractiveness Analysis 14.4.1.1.1. By Country 14.4.1.1.2. By Biomarker 14.4.1.1.3. By Diagnostic Technique 14.4.1.1.4. By End User 14.5. Market Trends 14.6. Key Market Participants - Intensity Mapping 14.7. Drivers and Restraints - Impact Analysis 14.8. Country-Level Analysis & Forecast 14.8.1. Mexico Market Analysis 14.8.1.1. Introduction 14.8.1.2. Market Analysis and Forecast By Market Taxonomy 14.8.1.2.1. By Biomarker 14.8.1.2.2. By Diagnostic Technique 14.8.1.2.3. By End User 14.8.2. Brazil Market Analysis 14.8.2.1. Introduction 14.8.2.2. Market Analysis and Forecast By Market Taxonomy 14.8.2.2.1. By Country 14.8.2.2.2. By Biomarker 14.8.2.2.3. By Diagnostic Technique 14.8.2.2.4. By End User 14.8.3. Argentina Market Analysis 14.8.3.1. Introduction 14.8.3.2. Market Analysis and Forecast By Market Taxonomy 14.8.3.2.1. By Biomarker 14.8.3.2.2. By Diagnostic Technique 14.8.3.2.3. By End User 15. Europe Market Analysis 2012 to 2021 and Forecast 2022 to 2032 15.1. Introduction 15.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2012 to 2021 15.3. Current and Future Market Size (US$ Million) Analysis & Forecast By Market Taxonomy, 2022 to 2032 15.3.1. By Country 15.3.1.1. Germany 15.3.1.2. Italy 15.3.1.3. France 15.3.1.4. The UK 15.3.1.5. Spain 15.3.1.6. BENELUX 15.3.1.7. Russia 15.3.1.8. Rest of Europe 15.3.2. By Biomarker 15.3.3. By Diagnostic Technique 15.3.4. By End User 15.4. Market Attractiveness Analysis 15.4.1. By Country 15.4.2. By Biomarker 15.4.3. By Diagnostic Technique 15.4.4. By End User 15.5. Market Trends 15.6. Key Market Participants - Intensity Mapping 15.7. Drivers and Restraints - Impact Analysis 15.8. Country-Level Analysis & Forecast 15.8.1. Germany Market Analysis 15.8.1.1. Introduction 15.8.1.2. Market Analysis and Forecast By Market Taxonomy 15.8.1.2.1. By Biomarker 15.8.1.2.2. By Diagnostic Technique 15.8.1.2.3. By End User 15.8.2. Italy Market Analysis 15.8.2.1. Introduction 15.8.2.2. Market Analysis and Forecast By Market Taxonomy 15.8.2.2.1. By Biomarker 15.8.2.2.2. By Diagnostic Technique 15.8.2.2.3. By End User 15.8.3. France Market Analysis 15.8.3.1. Introduction 15.8.3.2. Market Analysis and Forecast By Market Taxonomy 15.8.3.2.1. By Biomarker 15.8.3.2.2. By Diagnostic Technique 15.8.3.2.3. By End User 15.8.4. The UK Market Analysis 15.8.4.1. Introduction 15.8.4.2. Market Analysis and Forecast By Market Taxonomy 15.8.4.2.1. By Biomarker 15.8.4.2.2. By Diagnostic Technique 15.8.4.2.3. By End User 15.8.5. Spain Market Analysis 15.8.5.1. Introduction 15.8.5.2. Market Analysis and Forecast By Market Taxonomy 15.8.5.2.1. By Biomarker 15.8.5.2.2. By Diagnostic Technique 15.8.5.2.3. By End User 15.8.6. BENELUX Market Analysis 15.8.6.1. Introduction 15.8.6.2. Market Analysis and Forecast By Market Taxonomy 15.8.6.2.1. By Biomarker 15.8.6.2.2. By Diagnostic Technique 15.8.6.2.3. By End User 15.8.7. Russia Market Analysis 15.8.7.1. Introduction 15.8.7.2. Market Analysis and Forecast By Market Taxonomy 15.8.7.2.1. By Biomarker 15.8.7.2.2. By Diagnostic Technique 15.8.7.2.3. By End User 16. East Asia Market Analysis 2012 to 2021 and Forecast 2022 to 2032 16.1. Introduction 16.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2012 to 2021 16.3. Current and Future Market Size (US$ Million) Analysis & Forecast By Market Taxonomy, 2022 to 2032 16.3.1. By Country 16.3.1.1. China 16.3.1.2. Japan 16.3.1.3. South Korea 16.3.2. By Biomarker 16.3.3. By Diagnostic Technique 16.3.4. By End User 16.4. Market Attractiveness Analysis 16.4.1. By Country 16.4.2. By Biomarker 16.4.3. By Diagnostic Technique 16.4.4. By End User 16.5. Market Trends 16.6. Key Market Participants - Intensity Mapping 16.7. Drivers and Restraints - Impact Analysis 16.8. Country-Level Analysis & Forecast 16.8.1. China Market Analysis 16.8.1.1. Introduction 16.8.1.2. Market Analysis and Forecast By Market Taxonomy 16.8.1.2.1. By Biomarker 16.8.1.2.2. By Diagnostic Technique 16.8.1.2.3. By End User 16.8.2. Japan Market Analysis 16.8.2.1. Introduction 16.8.2.2. Market Analysis and Forecast By Market Taxonomy 16.8.2.2.1. By Biomarker 16.8.2.2.2. By Diagnostic Technique 16.8.2.2.3. By End User 16.8.3. South Korea Market Analysis 16.8.3.1. Introduction 16.8.3.2. Market Analysis and Forecast By Market Taxonomy 16.8.3.2.1. By Biomarker 16.8.3.2.2. By Diagnostic Technique 16.8.3.2.3. By End User 17. South Asia Market Analysis 2012 to 2021 and Forecast 2022 to 2032 17.1. Introduction 17.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2012 to 2021 17.3. Current and Future Market Size (US$ Million) Analysis & Forecast By Market Taxonomy, 2022 to 2032 17.3.1. By Country 17.3.1.1. India 17.3.1.2. Indonesia 17.3.1.3. Malaysia 17.3.1.4. Thailand 17.3.1.5. Rest of South Asia 17.3.2. By Biomarker 17.3.3. By Diagnostic Technique 17.3.4. By End User 17.4. Market Attractiveness Analysis 17.4.1. By Country 17.4.2. By Biomarker 17.4.3. By Diagnostic Technique 17.4.4. By End User 17.5. Market Trends 17.6. Key Market Participants - Intensity Mapping 17.7. Drivers and Restraints - Impact Analysis 17.8. Country-Level Analysis & Forecast 17.8.1. India Market Analysis 17.8.1.1. Introduction 17.8.1.2. Market Analysis and Forecast By Market Taxonomy 17.8.1.2.1. By Biomarker 17.8.1.2.2. By Diagnostic Technique 17.8.1.2.3. By End User 17.8.2. Indonesia Market Analysis 17.8.2.1. Introduction 17.8.2.2. Market Analysis and Forecast By Market Taxonomy 17.8.2.2.1. By Biomarker 17.8.2.2.2. By Diagnostic Technique 17.8.2.2.3. By End User 17.8.3. Malaysia Market Analysis 17.8.3.1. Introduction 17.8.3.2. Market Analysis and Forecast By Market Taxonomy 17.8.3.2.1. By Biomarker 17.8.3.2.2. By Diagnostic Technique 17.8.3.2.3. By End User 17.8.4. Thailand Market Analysis 17.8.4.1. Introduction 17.8.4.2. Market Analysis and Forecast By Market Taxonomy 17.8.4.2.1. By Biomarker 17.8.4.2.2. By Diagnostic Technique 17.8.4.2.3. By End User 18. Oceania Market 2012 to 2021 and Forecast 2022-2032 18.1. Introduction 18.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2012 to 2021 18.3. Current and Future Market Size (US$ Million) Analysis & Forecast By Market Taxonomy, 2022 to 2032 18.3.1. By Country 18.3.1.1. Australia 18.3.1.2. New Zealand 18.3.2. By Biomarker 18.3.3. By Diagnostic Technique 18.3.4. By End User 18.4. Market Attractiveness Analysis 18.4.1. By Country 18.4.2. By Biomarker 18.4.3. By Diagnostic Technique 18.4.4. By End User 18.5. Key Market Participants - Intensity Mapping 18.6. Drivers and Restraints - Impact Analysis 18.7. Country-Level Analysis & Forecast 18.7.1. Australia Market Analysis 18.7.1.1. Introduction 18.7.1.2. Market Analysis and Forecast By Market Taxonomy 18.7.1.2.1. By Biomarker 18.7.1.2.2. By Diagnostic Technique 18.7.1.2.3. By End User 18.7.2. New Zealand Market Analysis 18.7.2.1. Introduction 18.7.2.2. Market Analysis and Forecast By Market Taxonomy 18.7.2.2.1. By Biomarker 18.7.2.2.2. By Diagnostic Technique 18.7.2.2.3. By End User 19. Middle East and Africa (MEA) Market Analysis 2012 to 2021 and Forecast 2022 to 2032 19.1. Introduction 19.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2012 to 2021 19.3. Current and Future Market Size (US$ Million) Analysis & Forecast By Market Taxonomy, 2022 to 2032 19.3.1. By Country 19.3.1.1. GCC Countries 19.3.1.2. Turkey 19.3.1.3. South Africa 19.3.1.4. North Africa 19.3.1.5. Rest of Middle East and Africa 19.3.2. By Biomarker 19.3.3. By Diagnostic Technique 19.3.4. By End User 19.4. Market Attractiveness Analysis 19.4.1. By Country 19.4.2. By Biomarker 19.4.3. By Diagnostic Technique 19.4.4. By End User 19.5. Market Trends 19.6. Key Market Participants - Intensity Mapping 19.7. Drivers and Restraints - Impact Analysis 19.8. Country-Level Analysis & Forecast 19.8.1. GCC Countries Market Analysis 19.8.1.1. Introduction 19.8.1.2. Market Analysis and Forecast By Market Taxonomy 19.8.1.2.1. By Biomarker 19.8.1.2.2. By Diagnostic Technique 19.8.1.2.3. By End User 19.8.2. Turkey Market Analysis 19.8.2.1. Introduction 19.8.2.2. Market Analysis and Forecast By Market Taxonomy 19.8.2.2.1. By Biomarker 19.8.2.2.2. By Diagnostic Technique 19.8.2.2.3. By End User 19.8.3. South Africa Market Analysis 19.8.3.1. Introduction 19.8.3.2. Market Analysis and Forecast By Market Taxonomy 19.8.3.2.1. By Biomarker 19.8.3.2.2. By Diagnostic Technique 19.8.3.2.3. By End User 19.8.4. North Africa Market Analysis 19.8.4.1. Introduction 19.8.4.2. Market Analysis and Forecast By Market Taxonomy 19.8.4.2.1. By Biomarker 19.8.4.2.2. By Diagnostic Technique 19.8.4.2.3. By End User 20. Market Structure Analysis 20.1. Market Analysis By Tier of Companies 20.2. Market Concentration 20.3. Market Share Analysis (%) of Top Players 20.4. Market Presence Analysis 21. Competition Analysis 21.1. Competition Dashboard 21.2. Competition Benchmarking 21.3. Competition Deep Dive 21.3.1. Abbott Laboratories 21.3.1.1. Overview 21.3.1.2. Product Portfolio 21.3.1.3. Sales Footprint 21.3.1.4. Key Financials 21.3.1.5. SWOT Analysis 21.3.1.6. Strategic Overview 21.3.2. BioPorto Diagnostics AS 21.3.2.1. Overview 21.3.2.2. Product Portfolio 21.3.2.3. Sales Footprint 21.3.2.4. Key Financials 21.3.2.5. SWOT Analysis 21.3.2.6. Strategic Overview 21.3.3. F. Hoffmann-La Roche AG 21.3.3.1. Overview 21.3.3.2. Product Portfolio 21.3.3.3. Sales Footprint 21.3.3.4. Key Financials 21.3.3.5. SWOT Analysis 21.3.3.6. Strategic Overview 21.3.4. Thermo Fisher Scientific Inc. 21.3.4.1. Overview 21.3.4.2. Product Portfolio 21.3.4.3. Sales Footprint 21.3.4.4. Key Financials 21.3.4.5. SWOT Analysis 21.3.4.6. Strategic Overview 21.3.5. Nexelis (Pacific Biomarkers) 21.3.5.1. Overview 21.3.5.2. Product Portfolio 21.3.5.3. Sales Footprint 21.3.5.4. Key Financials 21.3.5.5. SWOT Analysis 21.3.5.6. Strategic Overview 21.3.6. BioMérieux 21.3.6.1. Overview 21.3.6.2. Product Portfolio 21.3.6.3. Sales Footprint 21.3.6.4. Key Financials 21.3.6.5. SWOT Analysis 21.3.6.6. Strategic Overview 21.3.7. Sphingotec GmbH 21.3.7.1. Overview 21.3.7.2. Product Portfolio 21.3.7.3. Sales Footprint 21.3.7.4. Key Financials 21.3.7.5. SWOT Analysis 21.3.7.6. Strategic Overview 21.3.8. Randox Laboratories Ltd 21.3.8.1. Overview 21.3.8.2. Product Portfolio 21.3.8.3. Sales Footprint 21.3.8.4. Key Financials 21.3.8.5. SWOT Analysis 21.3.8.6. Strategic Overview 21.3.9. Siemens Healthineers AG 21.3.9.1. Overview 21.3.9.2. Product Portfolio 21.3.9.3. Sales Footprint 21.3.9.4. Key Financials 21.3.9.5. SWOT Analysis 21.3.9.6. Strategic Overview 21.3.10. Beckman Coulter Inc. (Danaher Corporation) 21.3.10.1. Overview 21.3.10.2. Product Portfolio 21.3.10.3. Sales Footprint 21.3.10.4. Key Financials 21.3.10.5. SWOT Analysis 21.3.10.6. Strategic Overview 21.3.11. Bio-Rad Laboratories Inc. 21.3.11.1. Overview 21.3.11.2. Product Portfolio 21.3.11.3. Sales Footprint 21.3.11.4. Key Financials 21.3.11.5. SWOT Analysis 21.3.11.6. Strategic Overview 21.3.12. Enzo Biochem Inc. 21.3.12.1. Overview 21.3.12.2. Product Portfolio 21.3.12.3. Sales Footprint 21.3.12.4. Key Financials 21.3.12.5. SWOT Analysis 21.3.12.6. Strategic Overview 21.3.13. PerkinElmer Inc. 21.3.13.1. Overview 21.3.13.2. Product Portfolio 21.3.13.3. Sales Footprint 21.3.13.4. Key Financials 21.3.13.5. SWOT Analysis 21.3.13.6. Strategic Overview 21.3.14. Renalytix AI 21.3.14.1. Overview 21.3.14.2. Product Portfolio 21.3.14.3. Sales Footprint 21.3.14.4. Key Financials 21.3.14.5. SWOT Analysis 21.3.14.6. Strategic Overview 22. Assumptions and Acronyms Used 23. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
List of Tables
Table 01: Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, by Biomarker Table 02: Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032 by Diagnostic Technique Table 03: Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, by End User Table 04: Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, by Region Table 05: North America Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Country Table 06: North America Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Biomarker Table 07: North America Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Diagnostic Technique Table 08: North America Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by End User Table 09: Latin America Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Country Table 10: Latin America Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Biomarker Table 11: Latin America Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Diagnostic Technique Table 12: Latin America Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by End User Table 13: Europe Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Country Table 14: Europe Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Biomarker Table 15: Europe Market Analysis 2012 to 2021 and Forecast 2022 to 2032 by Diagnostic Technique Table 16: Europe Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by End User Table 17: East Asia Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Country Table 18: East Asia Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Biomarker Table 19: East Asia Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Diagnostic Technique Table 20: East Asia Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by End User Table 21: South Asia Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Country Table 22: South Asia Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Biomarker Table 23: South Asia Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Diagnostic Technique Table 24: South Asia Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by End User Table 25: Oceania Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Country Table 26: Oceania Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Biomarker Table 27: Oceania Market Analysis 2012 to 2021 and Forecast 2022 to 2032 by Diagnostic Technique Table 28: Oceania Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by End User Table 29: Middle East & Africa Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Country Table 30: Middle East & Africa Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Biomarker Table 31: Middle East & Africa Market Analysis 2012 to 2021 and Forecast 2022 to 2032 by Diagnostic Technique Table 32: Middle East & Africa Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by End User
Find your sweet spots for generating winning opportunities in this market.
List of Charts
Figure 01: Global Market Value (US$ Million) Analysis, 2012 to 2021 Figure 02: Global Market Forecast & Y-o-Y Growth, 2022 to 2032 Figure 03: Global Market Absolute $ Opportunity (US$ Million) Analysis, 2021 to 2032 Figure 04: Global Market Value Share (%) Analysis 2022 and 2032, by Biomarker Figure 05: Global Market Y-o-Y Growth (%) Analysis 2021 to 2032, by Biomarker Figure 06: Global Market Attractiveness Analysis 2022 to 2032, by Biomarker Figure 07: Global Market Value Share (%) Analysis 2022 and 2032, by Diagnostic Technique Figure 08: Global Market Y-o-Y Growth (%) Analysis 2021 to 2032, by Diagnostic Technique Figure 09: Global Market Attractiveness Analysis 2022 to 2032, by Diagnostic Technique Figure 10: Global Market Value Share (%) Analysis 2022 and 2032, by End User Figure 11: Global Market Y-o-Y Growth (%) Analysis 2021 to 2032, by End User Figure 12: Global Market Attractiveness Analysis 2022 to 2032, by End User Figure 13: Global Market Value Share (%) Analysis 2022 and 2032, by Region Figure 14: Global Market Y-o-Y Growth (%) Analysis 2021 to 2032, by Region Figure 15: Global Market Attractiveness Analysis 2022 to 2032, by Region Figure 16: North America Market Value (US$ Million) Analysis, 2012 to 2021 Figure 17: North America Market Value (US$ Million) Forecast, 2022 to 2032 Figure 18: North America Market Value Share, by Biomarker (2022 E) Figure 19: North America Market Value Share, by Diagnostic Technique (2022 E) Figure 20: North America Market Value Share, by End User (2022 E) Figure 21: North America Market Value Share, by Country (2022 E) Figure 22: North America Market Attractiveness Analysis by Biomarker, 2022 to 2032 Figure 23: North America Market Attractiveness Analysis by Diagnostic Technique, 2022 to 2032 Figure 24: North America Market Attractiveness Analysis by End User, 2022 to 2032 Figure 25: North America Market Attractiveness Analysis by Country, 2022 to 2032 Figure 26: The USA Market Value Proportion Analysis, 2021 Figure 27: Global Vs. The USA Growth Comparison Figure 28: The USA Market Share Analysis (%) by Biomarker, 2022 to 2032 Figure 29: The USA Market Share Analysis (%) by Diagnostic Technique, 2022 to 2032 Figure 30: The USA Market Share Analysis (%) by End User, 2022 to 2032 Figure 31: Canada Market Value Proportion Analysis, 2021 Figure 32: Global Vs. Canada. Growth Comparison Figure 33: Canada Market Share Analysis (%) by Biomarker, 2022 to 2032 Figure 34: Canada Market Share Analysis (%) by Diagnostic Technique, 2022 to 2032 Figure 35: Canada Market Share Analysis (%) by End User, 2022 to 2032 Figure 36: Latin America Market Value (US$ Million) Analysis, 2012 to 2021 Figure 37: Latin America Market Value (US$ Million) Forecast, 2022 to 2032 Figure 38: Latin America Market Value Share, by Biomarker (2022 E) Figure 39: Latin America Market Value Share, by Diagnostic Technique (2022 E) Figure 40: Latin America Market Value Share, by End User (2022 E) Figure 41: Latin America Market Value Share, by Country (2022 E) Figure 42: Latin America Market Attractiveness Analysis by Biomarker, 2022 to 2032 Figure 43: Latin America Market Attractiveness Analysis by Diagnostic Technique, 2022 to 2032 Figure 44: Latin America Market Attractiveness Analysis by End User, 2022 to 2032 Figure 45: Latin America Market Attractiveness Analysis by Country, 2022 to 2032 Figure 46: Mexico Market Value Proportion Analysis, 2021 Figure 47: Global Vs Mexico Growth Comparison Figure 48: Mexico Market Share Analysis (%) by Biomarker, 2022 to 2032 Figure 49: Mexico Market Share Analysis (%) by Diagnostic Technique, 2022 to 2032 Figure 50: Mexico Market Share Analysis (%) by End User, 2022 to 2032 Figure 51: Brazil Market Value Proportion Analysis, 2021 Figure 52: Global Vs. Brazil. Growth Comparison Figure 53: Brazil Market Share Analysis (%) by Biomarker, 2022 to 2032 Figure 54: Brazil Market Share Analysis (%) by Diagnostic Technique, 2022 to 2032 Figure 55: Brazil Market Share Analysis (%) by End User, 2022 to 2032 Figure 56: Argentina Market Value Proportion Analysis, 2021 Figure 57: Global Vs Argentina Growth Comparison Figure 58: Argentina Market Share Analysis (%) by Biomarker, 2022 to 2032 Figure 59: Argentina Market Share Analysis (%) by Diagnostic Technique, 2022 to 2032 Figure 60: Argentina Market Share Analysis (%) by End User, 2022 to 2032 Figure 61: Europe Market Value (US$ Million) Analysis, 2012 to 2021 Figure 62: Europe Market Value (US$ Million) Forecast, 2022 to 2032 Figure 63: Europe Market Value Share, by Biomarker (2022 E) Figure 64: Europe Market Value Share, by Diagnostic Technique (2022 E) Figure 65: Europe Market Value Share, by End User (2022 E) Figure 66: Europe Market Value Share, by Country (2022 E) Figure 67: Europe Market Attractiveness Analysis by Biomarker, 2022 to 2032 Figure 68: Europe Market Attractiveness Analysis by Diagnostic Technique, 2022 to 2032 Figure 69: Europe Market Attractiveness Analysis by End User, 2022 to 2032 Figure 70: Europe Market Attractiveness Analysis by Country, 2022 to 2032 Figure 71: The UK Market Value Proportion Analysis, 2021 Figure 72: Global Vs. The UK Growth Comparison Figure 73: The UK Market Share Analysis (%) by Biomarker, 2022 to 2032 Figure 74: The UK Market Share Analysis (%) by Diagnostic Technique, 2022 to 2032 Figure 75: The UK Market Share Analysis (%) by End User, 2022 to 2032 Figure 76: Germany Market Value Proportion Analysis, 2021 Figure 77: Global Vs. Germany Growth Comparison Figure 78: Germany Market Share Analysis (%) by Biomarker, 2022 to 2032 Figure 79: Germany Market Share Analysis (%) by Diagnostic Technique, 2022 to 2032 Figure 80: Germany Market Share Analysis (%) by End User, 2022 to 2032 Figure 81: Italy Market Value Proportion Analysis, 2021 Figure 82: Global Vs. Italy Growth Comparison Figure 83: Italy Market Share Analysis (%) by Biomarker, 2022 to 2032 Figure 84: Italy Market Share Analysis (%) by Diagnostic Technique, 2022 to 2032 Figure 85: Italy Market Share Analysis (%) by End User, 2022 to 2032 Figure 86: France Market Value Proportion Analysis, 2021 Figure 87: Global Vs France Growth Comparison Figure 88: France Market Share Analysis (%) by Biomarker, 2022 to 2032 Figure 89: France Market Share Analysis (%) by Diagnostic Technique, 2022 to 2032 Figure 90: France Market Share Analysis (%) by End User, 2022 to 2032 Figure 91: Spain Market Value Proportion Analysis, 2021 Figure 92: Global Vs Spain Growth Comparison Figure 93: Spain Market Share Analysis (%) by Biomarker, 2022 to 2032 Figure 94: Spain Market Share Analysis (%) by Diagnostic Technique, 2022 to 2032 Figure 95: Spain Market Share Analysis (%) by End User, 2022 to 2032 Figure 96: Russia Market Value Proportion Analysis, 2021 Figure 97: Global Vs Russia Growth Comparison Figure 98: Russia Market Share Analysis (%) by Biomarker, 2022 to 2032 Figure 99: Russia Market Share Analysis (%) by Diagnostic Technique, 2022 to 2032 Figure 100: Russia Market Share Analysis (%) by End User, 2022 to 2032 Figure 101: BENELUX Market Value Proportion Analysis, 2021 Figure 102: Global Vs BENELUX Growth Comparison Figure 103: BENELUX Market Share Analysis (%) by Biomarker, 2022 to 2032 Figure 104: BENELUX Market Share Analysis (%) by Diagnostic Technique, 2022 to 2032 Figure 105: BENELUX Market Share Analysis (%) by End User, 2022 to 2032 Figure 106: East Asia Market Value (US$ Million) Analysis, 2012 to 2021 Figure 107: East Asia Market Value (US$ Million) Forecast, 2022 to 2032 Figure 108: East Asia Market Value Share, by Biomarker (2022 E) Figure 109: East Asia Market Value Share, by Diagnostic Technique (2022 E) Figure 110: East Asia Market Value Share, by End User (2022 E) Figure 111: East Asia Market Value Share, by Country (2022 E) Figure 112: East Asia Market Attractiveness Analysis by Biomarker, 2022 to 2032 Figure 113: East Asia Market Attractiveness Analysis by Diagnostic Technique, 2022 to 2032 Figure 114: East Asia Market Attractiveness Analysis by End User, 2022 to 2032 Figure 115: East Asia Market Attractiveness Analysis by Country, 2022 to 2032 Figure 116: China Market Value Proportion Analysis, 2021 Figure 117: Global Vs. China Growth Comparison Figure 118: China Market Share Analysis (%) by Biomarker, 2022 to 2032 Figure 119: China Market Share Analysis (%) by Diagnostic Technique, 2022 to 2032 Figure 120: China Market Share Analysis (%) by End User, 2022 to 2032 Figure 121: Japan Market Value Proportion Analysis, 2021 Figure 122: Global Vs. Japan Growth Comparison Figure 123: Japan Market Share Analysis (%) by Biomarker, 2022 to 2032 Figure 124: Japan Market Share Analysis (%) by Diagnostic Technique, 2022 to 2032 Figure 125: Japan Market Share Analysis (%) by End User, 2022 to 2032 Figure 126: South Korea Market Value Proportion Analysis, 2021 Figure 127: Global Vs South Korea Growth Comparison Figure 128: South Korea Market Share Analysis (%) by Biomarker, 2022 to 2032 Figure 129: South Korea Market Share Analysis (%) by Diagnostic Technique, 2022 to 2032 Figure 130: South Korea Market Share Analysis (%) by End User, 2022 to 2032 Figure 131: South Asia Market Value (US$ Million) Analysis, 2012 to 2021 Figure 132: South Asia Market Value (US$ Million) Forecast, 2022 to 2032 Figure 133: South Asia Market Value Share, by Biomarker (2022 E) Figure 134: South Asia Market Value Share, by Diagnostic Technique (2022 E) Figure 135: South Asia Market Value Share, by End User (2022 E) Figure 136: South Asia Market Value Share, by Country (2022 E) Figure 137: South Asia Market Attractiveness Analysis by Biomarker, 2022 to 2032 Figure 138: South Asia Market Attractiveness Analysis by Diagnostic Technique, 2022 to 2032 Figure 139: South Asia Market Attractiveness Analysis by End User, 2022 to 2032 Figure 140: South Asia Market Attractiveness Analysis by Country, 2022 to 2032 Figure 141: India Market Value Proportion Analysis, 2021 Figure 142: Global Vs. India Growth Comparison Figure 143: India Market Share Analysis (%) by Biomarker, 2022 to 2032 Figure 144: India Market Share Analysis (%) by Diagnostic Technique, 2022 to 2032 Figure 145: India Market Share Analysis (%) by End User, 2022 to 2032 Figure 146: Indonesia Market Value Proportion Analysis, 2021 Figure 147: Global Vs. Indonesia Growth Comparison Figure 148: Indonesia Market Share Analysis (%) by Biomarker, 2022 to 2032 Figure 149: Indonesia Market Share Analysis (%) by Diagnostic Technique, 2022 to 2032 Figure 150: Indonesia Market Share Analysis (%) by End User, 2022 to 2032 Figure 151: Malaysia Market Value Proportion Analysis, 2021 Figure 152: Global Vs. Malaysia Growth Comparison Figure 153: Malaysia Market Share Analysis (%) by Biomarker, 2022 to 2032 Figure 154: Malaysia Market Share Analysis (%) by Diagnostic Technique, 2022 to 2032 Figure 155: Malaysia Market Share Analysis (%) by End User, 2022 to 2032 Figure 156: Thailand Market Value Proportion Analysis, 2021 Figure 157: Global Vs. Thailand Growth Comparison Figure 158: Thailand Market Share Analysis (%) by Biomarker, 2022 to 2032 Figure 159: Thailand Market Share Analysis (%) by Diagnostic Technique, 2022 to 2032 Figure 160: Thailand Market Share Analysis (%) by End User, 2022 to 2032 Figure 161: Oceania Market Value (US$ Million) Analysis, 2012 to 2021 Figure 162: Oceania Market Value (US$ Million) Forecast, 2022 to 2032 Figure 163: Oceania Market Value Share, by Biomarker (2022 E) Figure 164: Oceania Market Value Share, by Diagnostic Technique (2022 E) Figure 165: Oceania Market Value Share, by End User (2022 E) Figure 166: Oceania Market Value Share, by Country (2022 E) Figure 167: Oceania Market Attractiveness Analysis by Biomarker, 2022 to 2032 Figure 168: Oceania Market Attractiveness Analysis by Diagnostic Technique, 2022 to 2032 Figure 169: Oceania Market Attractiveness Analysis by End User, 2022 to 2032 Figure 170: Oceania Market Attractiveness Analysis by Country, 2022 to 2032 Figure 171: Australia Market Value Proportion Analysis, 2021 Figure 172: Global Vs. Australia Growth Comparison Figure 173: Australia Market Share Analysis (%) by Biomarker, 2022 to 2032 Figure 174: Australia Market Share Analysis (%) by Diagnostic Technique, 2022 to 2032 Figure 175: Australia Market Share Analysis (%) by End User, 2022 to 2032 Figure 176: New Zealand Market Value Proportion Analysis, 2021 Figure 177: Global Vs New Zealand Growth Comparison Figure 178: New Zealand Market Share Analysis (%) by Biomarker, 2022 to 2032 Figure 179: New Zealand Market Share Analysis (%) by Diagnostic Technique, 2022 to 2032 Figure 180: New Zealand Market Share Analysis (%) by End User, 2022 to 2032 Figure 181: Middle East & Africa Market Value (US$ Million) Analysis, 2012 to 2021 Figure 182: Middle East & Africa Market Value (US$ Million) Forecast, 2022 to 2032 Figure 183: Middle East & Africa Market Value Share, by Biomarker (2022 E) Figure 184: Middle East & Africa Market Value Share, by Diagnostic Technique (2022 E) Figure 185: Middle East & Africa Market Value Share, by End User (2022 E) Figure 186: Middle East & Africa Market Value Share, by Country (2022 E) Figure 187: Middle East & Africa Market Attractiveness Analysis by Biomarker, 2022 to 2032 Figure 188: Middle East & Africa Market Attractiveness Analysis by Diagnostic Technique, 2022 to 2032 Figure 189: Middle East & Africa Market Attractiveness Analysis by End User, 2022 to 2032 Figure 190: Middle East & Africa Market Attractiveness Analysis by Country, 2022 to 2032 Figure 191: GCC Countries Market Value Proportion Analysis, 2021 Figure 192: Global Vs GCC Countries Growth Comparison Figure 193: GCC Countries Market Share Analysis (%) by Biomarker, 2022 to 2032 Figure 194: GCC Countries Market Share Analysis (%) by Diagnostic Technique, 2022 to 2032 Figure 195: GCC Countries Market Share Analysis (%) by End User, 2022 to 2032 Figure 196: Turkey Market Value Proportion Analysis, 2021 Figure 197: Global Vs. Turkey Growth Comparison Figure 198: Turkey Market Share Analysis (%) by Biomarker, 2022 to 2032 Figure 199: Turkey Market Share Analysis (%) by Diagnostic Technique, 2022 to 2032 Figure 200: Turkey Market Share Analysis (%) by End User, 2022 to 2032 Figure 201: South Africa Market Value Proportion Analysis, 2021 Figure 202: Global Vs. South Africa Growth Comparison Figure 203: South Africa Market Share Analysis (%) by Biomarker, 2022 to 2032 Figure 204: South Africa Market Share Analysis (%) by Diagnostic Technique, 2022 to 2032 Figure 205: South Africa Market Share Analysis (%) by End User, 2022 to 2032 Figure 206: North Africa Market Value Proportion Analysis, 2021 Figure 207: Global Vs North Africa Growth Comparison Figure 208: North Africa Market Share Analysis (%) by Biomarker, 2022 to 2032 Figure 209: North Africa Market Share Analysis (%) by Diagnostic Technique, 2022 to 2032 Figure 210: North Africa Market Share Analysis (%) by End User, 2022 to 2032
Recommendations
Explore Healthcare Insights
View Reports
